Discovery and Biological Activity of 6BrCaQ As an Inhibitor of the Hsp90 Protein Folding Machinery
Overview
Authors
Affiliations
Heat shock protein 90 (Hsp90) is a significant target in the development of rational cancer therapy, due to its role at the crossroads of multiple signaling pathways associated with cell proliferation and viability. Here, a novel series of Hsp90 inhibitors containing a quinolein-2-one scaffold was synthesized and evaluated in cell proliferation assays. Results from these structure-activity relationships studies enabled identification of the simplified 3-aminoquinolein-2-one analogue 2 b (6BrCaQ), which manifests micromolar activity against a panel of cancer cell lines. The molecular signature of Hsp90 inhibition was assessed by depletion of standard known Hsp90 client proteins. Finally, processing and activation of caspases 7, 8, and 9, and the subsequent cleavage of PARP by 6BrCaQ, suggest stimulation of apoptosis through both extrinsic and intrinsic pathways.
Novel Multi-Target Agents Based on the Privileged Structure of 4-Hydroxy-2-quinolinone.
Kostopoulou I, Tzani A, Chronaki K, Prousis K, Pontiki E, Hadjiplavlou-Litina D Molecules. 2024; 29(1).
PMID: 38202773 PMC: 10780633. DOI: 10.3390/molecules29010190.
Singh S, Chakrabortty G, Raha Roy S Chem Sci. 2023; 14(44):12541-12547.
PMID: 38020365 PMC: 10646921. DOI: 10.1039/d3sc04447e.
Chakraborty A, Mohapatra S, Barik S, Roy I, Gupta B, Biswas A Biosci Rep. 2023; 43(2).
PMID: 36630532 PMC: 9905792. DOI: 10.1042/BSR20220324.
Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications.
Ardestani M, Khorsandi Z, Keshavarzipour F, Iravani S, Sadeghi-Aliabadi H, Varma R Pharmaceutics. 2022; 14(10).
PMID: 36297655 PMC: 9610671. DOI: 10.3390/pharmaceutics14102220.
Mathieu C, Messaoudi S, Fattal E, Vergnaud-Gauduchon J Cancer Drug Resist. 2022; 2(3):381-398.
PMID: 35582577 PMC: 8992530. DOI: 10.20517/cdr.2019.26.